Table 2.
Effect of Chy on day 4 ELT and day 5 time spent in target quadrant (TSTQ) of mice using MWM.
| Group | Treatment | Dose | Day 1 ELT (s) | Day 4 ELT (s) | Day 5 TSTQ (s) |
|---|---|---|---|---|---|
| I | Control (normal) | Standard diet | 69.7 ± 2.4 | 25.6 ± 1.8a | 73.4 ± 3.6 |
| II | Chy | 1% w/w, in diet | 68.6 ± 1.6 | 24.2 ± 2.4 | 70.6 ± 4.2 |
| III | Chy | 2% w/w, in diet | 65.6 ± 0.6 | 26.7 ± 2.9 | 72.8 ± 2.4 |
| IV | Piracetam | 400 mg kg−1; i.p. | 67.9 ± 3.9 | 13.4 ± 3.1b | 89.9 ± 2.2e |
| V | Sco | 1.4 mg kg−1; i.p. | 66.3 ± 3.5 | 56.2 ± 3.6b | 29.2 ± 4.9e |
| VI | Chy + Sco | 1% w/w, in diet + 1.4 mg kg−1; i.p. | 64.3 ± 1.2 | 34.8 ± 2.1c | 52.1 ± 1.8f |
| VII | Chy + Sco | 2% w/w, in diet + 1.4 mg kg−1; i.p. | 62.1 ± 4.3 | 25.4 ± 1.3c | 61.2 ± 4.6f |
| VIII | Piracetam + Sco | 400 mg kg−1; i.p. + 1.4 mg kg−1; i.p. | 62.3 ± 2.9 | 14.4 ± 2.7c | 66.3 ± 2.8f |
| IX | Alp | 0.5 mg kg−1; i.p. | 63.4 ± 2.9 | 59.9 ± 4.3b | 24.3 ± 1.2e |
| X | Chy + Alp | 1% w/w, in diet + 0.5 mg kg−1; i.p. | 63.7 ± 2.7 | 32.1 ± 1.6d | 54.2 ± 3.2g |
| XI | Chy + Alp | 2% w/w, in diet + 0.5 mg kg−1; i.p. | 60.1 ± 2.5 | 22.1 ± 4.1d | 64.6 ± 3.7g |
| XII | Piracetam + Alp | 400 mg kg−1; i.p. + 0.5 mg kg−1; i.p. | 66.3 ± 1.9 | 17.3 ± 2.3d | 69.1 ± 3.6g |
Piracetam (400 mg kg−1; i.p.) is used as a standard drug. Values are mean ± SEM.
a P < .05 as compared to day 1 ELT in control.
b P < .05 as compared to day 4 ELT in control.
c P < .05 as compared with day 4 ELT in Sco group.
d P < .05 as compared with day 4 ELT in Alp group.
e P < .05 as compared to day 5 TSTQ in control.
f P < .05 as compared with day 5 TSTQ in Sco group.
g P < .05 as compared with day 5 TSTQ in Alp group.